London: US drugs giant Pfizer announced it has made a final improved bid for British competitor AstraZeneca, valuing the company at 69 billion (USD 117 billion).
The offer of Rs.55 a share is 15 per cent higher than its last bid, made on May 2, and also is the fourth and final approach, Pfizer said yesterday, but added it did not expect the AstraZeneca board to accept the new deal.
